The SEQUOIA study's 5-year follow-up confirms zanubrutinib's safety profile and low cardiovascular events in treatment-naive chronic lymphocytic leukemia, according to Mazyar Shadman, MD, MPH, of Fred ...
Clinical trials have used various doses and treatment ... The dose administered to patients with CLL in the phase 3 trial was 100 mg/m 2 daily on 2 consecutive days every 28 days ( Table 1).
the available clinical data shed little light on its role in the treatment of CLL. Adverse effects include myelosuppression and gastrointestinal complaints. In a recent phase III trial of ...
If you’ve received a CLL diagnosis, you may want to consider participating in a clinical trial. CLL progression and severity can vary significantly from person to person, and clinical trials ...
Researchers found no significant differences in the risk of overall adverse events (AEs), but there were significant differences in grade 3 or higher AEs, serious AEs, treatment discontinuations due ...